Scholar Rock Holding Corp
Close on Oct 19, 2026
- Market cap
- $5.26B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.83 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | – | $-0.88 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | $-0.90 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | $-0.98 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-0.67 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.66 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.60 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-0.59 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Press releases
Announcements Scholar Rock filed with the SEC
FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2026 Scholar Rock, Inc. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2026 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Scholar Rock Resubmits Biologics License Application
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Scholar Rock Reports Fourth Quarter and Full
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Scholar Rock Highlights 2026 Strategic Priorities
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2026 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Scholar Rock Appoints David L. Hallal as Chief
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Scholar Rock Announces the Appointment of Industry
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 Scholar Rock, Inc. All rights reserved.
Other events · EX-99.1 to Form 8-K
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
Results of operations · Other events · EX-99.1 to Form 8-K
© 2024 Scholar Rock, Inc. All rights reserved.
Results of operations · Other events · EX-99.2 to Form 8-K
Scholar Rock Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports Apitegromab Meets Primary
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2024 Scholar Rock, Inc. All rights reserved. Positive Topline Results from Pivotal Phase 3 SAPPHIRE Trial of Apitegromab in Spinal Muscular Atrophy (SMA) October 7, 2024 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
Results of operations · Other events · EX-99.1 to Form 8-K
© 2024 Scholar Rock, Inc. All rights reserved.
Results of operations · Other events · EX-99.2 to Form 8-K
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
The Anti-Myostatin Antibody SRK-439 Promotes Healthy
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2024 Scholar Rock, Inc. All rights reserved.
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
Results of operations · EX-99.1 to Form 8-K